KBLB Kraig Biocraft Laboratories Inc.

Kraig Biocraft Laboratories tackles biggest challenge facing Global Silk Production

Kraig Biocraft Laboratories tackles biggest challenge facing Global Silk Production

ANN ARBOR, Mich., June 29, 2020 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), a leading developer of spider silk based fibers, announces that it has completed the development phase of a new program targeting the largest challenge facing global silk production, viral pathogens. As reported in the Journal of Biological Control, volume 31, viral diseases can result in total annual silk production losses of as much as 32%. 

Kraig Labs has developed its first immune-enhancing genetic insert, designed to create disease-resistant silkworms. The Company is now ready for its first round of transgenic creation and resistance testing. This effort was done in a parallel, and complementary, effort to the Company’s groundbreaking program developing high-performance spider silk inspired silk fibers and yarns.

Global silk production is expected to reach USD 17 billion in 2021; the economic impact of eliminating the loss from disease is a multi-billion dollar opportunity. The Company anticipates that its development of a disease resistant silkworm could be licensed across the entire global silk industry.

“Our work to enhance the disease resistance of our silkworms complements and strengths our focus in bringing our recombinant spider silk to market,” said CEO and Founder, Kim Thompson. “We believe that success in this effort will also provide significant opportunities for growth far beyond the reach of Kraig’s in-house production capacity, with licensing applications globally.”

Once proven, the Company expects to merge these disease resistance properties within its existing lines of genetically enhanced recombinant spider silks.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

EN
29/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kraig Biocraft Laboratories Inc.

 PRESS RELEASE

From Lab Fiber to Luxury Fabric: Kraig Biocraft Laboratories Targets A...

From Lab Fiber to Luxury Fabric: Kraig Biocraft Laboratories Targets Apparel First with Engineered Spider Silk DENVER, April 02, 2026 (GLOBE NEWSWIRE) -- () -- Kraig Biocraft Laboratories (OTCQB: KBLB) is advancing a transgenic silkworm platform designed to produce recombinant spider silk at commercial scale, positioning the company at the intersection of genetic engineering, materials science, and textile manufacturing. Spider silk has long been studied for its combination of strength, elasticity, and low weight. The challenge has been producing it economically at scale. Kraig’s approac...

 PRESS RELEASE

Kraig Biocraft Laboratories Deploys Over 700,000 BAM-1 Alpha Productio...

Kraig Biocraft Laboratories Deploys Over 700,000 BAM-1 Alpha Production Hybrids, Achieving Key Milestone in its Aggressive Scale-Up Plan ANN ARBOR, Mich., March 30, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced the successful deployment of more than 700,000 BAM-1 Alpha production hybrids of its previously reported 1,000,000 egg inventory. These silkworms are now in active production. This achievement underscores the Company's continued execution of its previou...

 PRESS RELEASE

Kraig Biocraft Laboratories Increases R&D Capacity, as Project Atlas B...

Kraig Biocraft Laboratories Increases R&D Capacity, as Project Atlas Breakthroughs Creating New Spider Silk Transgenics ANN ARBOR, Mich., March 23, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a significant expansion of its research and development capacity designed to keep pace with rapid progress of its advanced materials initiative, Project Atlas. The Company has expanded its laboratory capabilities, onboarding new scientific personnel and the deploymen...

 PRESS RELEASE

Engineered Silkworms Spin Spider Silk as Biotech Firm Targets Commerci...

Engineered Silkworms Spin Spider Silk as Biotech Firm Targets Commercial Scale DENVER, March 18, 2026 (GLOBE NEWSWIRE) --  -- A biotechnology company developing genetically engineered silkworms says it’s moving toward commercial production of spider silk, a material long sought by researchers for its unusual combination of strength and elasticity. Kraig Biocraft Laboratories (OTCQB: KBLB) deployed one million genetically engineered silkworm eggs across multiple production facilities in Vietnam as part of a Spring scale-up effort that could eventually produce around 10 metric tons of reco...

 PRESS RELEASE

24/7 Market News: Kraig Labs the Bootstrapped Unicorn in the Making

24/7 Market News: Kraig Labs the Bootstrapped Unicorn in the Making DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- -- In technology and biotechnology, “unicorn” status is typically reserved for private companies valued at $1 billion or more; often backed by major venture rounds, institutional syndicates, and aggressive capital deployment strategies. But what happens when a company advances a platform with billion-dollar potential without the backing of Silicon Valley mega-funding? That question is increasingly being asked about Kraig Biocraft Laboratories (OTCQB: KBLB). More than a decade ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch